Medtronic Expands Surgical Synergy(SM) with FDA Clearance of the Stealth Autoguide™ System for Cranial Procedures
December 18 2019 - 7:00AM
Medtronic plc (NYSE:MDT) announced that the U.S. Food and
Drug Administration (FDA) recently cleared the Stealth Autoguide™
system, the first cranial robotic platform that integrates with
Medtronic’s enabling technology portfolio to create an end-to-end
procedural solution. The Stealth Autoguide Platform is a robotic
guidance system intended for the spatial positioning and
orientation of instrument holders or tool guides used in
neurosurgical procedures.
The Stealth Autoguide Platform is cleared for
biopsy procedures, stereoelectroencephalography (sEEG) depth
electrode placement, and for the positioning of the Visualase™ bone
anchor, which is used for catheter placement. These solutions are
part of the company’s market-leading Surgical Synergy platform,
which integrates Medtronic technologies to create consistent,
predictable, and reproducible procedures.
"Medtronic continues to deliver on its commitment
of developing innovative technologies that helps physicians
seamlessly provide high-quality care for cranial and other
procedures," said P. David Adelson, division chief of Neurosurgery
and director of Barrow Neurological Institute at Phoenix Children’s
Hospital. "The precision provided by the Stealth Autoguide system
will help my clinical team accomplish unique surgical scenarios
with increased accuracy.”
Stealth Autoguide system integrates with
StealthStation™ Image Guidance systems and the Midas Rex™
high-speed surgical drill platform. The navigation software
optimizes the surgical workflow, providing continuous real-time
navigation and visual feedback on the robotic alignment for
improved efficiency. The system provides visualization throughout
the entire procedure, even while drilling, with the ability to
drill on the axis of a surgical plan.
“The Stealth Autoguide Platform provides surgeons
and operating room staff with robotic-assisted positioning and
trajectory guidance for cranial procedures confirming consistent,
repeatable, and accurate alignment to their surgical plans,” said
Dave Anderson, vice president and general manager, Enabling
Technologies, which is part of the Restorative Therapies Group at
Medtronic. “The Stealth Autoguide Platform showcases Medtronic’s
commitment to advancing care and delivering the best outcomes to
the most patients possible through our Surgical Synergy
platform.”
About MedtronicMedtronic
plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 90,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to
risks and uncertainties such as those described in Medtronic's
periodic reports on file with the Securities and Exchange
Commission. Actual results may differ materially from anticipated
results.
-end-
David T. YoungPublic Relations+1-774-284-2746
Ryan WeispfenningInvestor Relations+1-763-505-4626
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024